Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol., 27 February 2024

Sec. Experimental Pharmacology and Drug Discovery

Volume 15 - 2024 | https://doi.org/10.3389/fphar.2024.1345645

RETRACTED: Rhodomyrtus tomentosa as a new anticancer molecular strategy in breast histology via Her2, IL33, EGFR, and MUC1

Retracted
  • 1Study Program of Biology, Faculty of Mathematics and Natural Sciences, Universitas Sumatera Utara, Medan, Indonesia
  • 2Department of Pharmacology, Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia
  • 3Research Center for Food Technology and Processing, National Research and Innovation Agency (BRIN), Yogyakarta, Indonesia
  • 4Department of Orthodontics, Faculty of Dental Medicine, Universitas Airlangga, Surabaya, Indonesia
  • 5Research Center for Animal Husbandry, National Research and Innovation Agency (BRIN), Bogor, Indonesia

Citation: Situmorang PC, Ilyas S, Syahputra RA, Sari RM, Nugraha AP and Ibrahim A (2024) Rhodomyrtus tomentosa as a new anticancer molecular strategy in breast histology via Her2, IL33, EGFR, and MUC1. Front. Pharmacol. 15:1345645. doi: 10.3389/fphar.2024.1345645

Received: 30 November 2023; Accepted: 19 February 2024;
Published: 27 February 2024; Retracted: 29 January 2026.

Edited by:

Onur Bender, Ankara University, Türkiye

Reviewed by:

Dana Carmen Zaha, University of Oradea, Romania
Sirajudheen Anwar, University of Hail, Saudi Arabia

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.